NO20014519L - Apomorfin- og sildenafilpreparat - Google Patents

Apomorfin- og sildenafilpreparat

Info

Publication number
NO20014519L
NO20014519L NO20014519A NO20014519A NO20014519L NO 20014519 L NO20014519 L NO 20014519L NO 20014519 A NO20014519 A NO 20014519A NO 20014519 A NO20014519 A NO 20014519A NO 20014519 L NO20014519 L NO 20014519L
Authority
NO
Norway
Prior art keywords
apomorphine
sildenafil
administered
treatment
preparation
Prior art date
Application number
NO20014519A
Other languages
English (en)
Other versions
NO324511B1 (no
NO20014519D0 (no
Inventor
Ragab El-Rashidy
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of NO20014519D0 publication Critical patent/NO20014519D0/no
Publication of NO20014519L publication Critical patent/NO20014519L/no
Publication of NO324511B1 publication Critical patent/NO324511B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20014519A 1999-03-16 2001-09-17 Anvendelse av apomorfin og sildenafil for fremstilling av et medikament for behandling av erektil dysfunksjon NO324511B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/270,035 US6087362A (en) 1999-03-16 1999-03-16 Apomorphine and sildenafil composition
PCT/US2000/006654 WO2000054774A1 (en) 1999-03-16 2000-03-14 Apomorphine and sildenafil composition

Publications (3)

Publication Number Publication Date
NO20014519D0 NO20014519D0 (no) 2001-09-17
NO20014519L true NO20014519L (no) 2001-10-25
NO324511B1 NO324511B1 (no) 2007-11-05

Family

ID=23029614

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014519A NO324511B1 (no) 1999-03-16 2001-09-17 Anvendelse av apomorfin og sildenafil for fremstilling av et medikament for behandling av erektil dysfunksjon

Country Status (21)

Country Link
US (1) US6087362A (no)
EP (1) EP1173178B1 (no)
JP (1) JP2002539163A (no)
CN (1) CN1350454A (no)
AT (1) ATE302003T1 (no)
AU (1) AU3744500A (no)
BR (1) BR0009016A (no)
CA (1) CA2367605A1 (no)
CZ (1) CZ20013344A3 (no)
DE (1) DE60022021T2 (no)
DK (1) DK1173178T3 (no)
ES (1) ES2244418T3 (no)
HU (1) HUP0200549A3 (no)
IL (1) IL145487A0 (no)
MX (1) MXPA01009332A (no)
NO (1) NO324511B1 (no)
NZ (1) NZ514464A (no)
PL (1) PL350313A1 (no)
PT (1) PT1173178E (no)
WO (1) WO2000054774A1 (no)
ZA (1) ZA200107920B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
ES2341090T3 (es) * 2000-08-30 2010-06-15 Unimed Pharmaceuticals, Llc Procedimiento para tratar la disfuncion erectil y aumentar la libido en hombres.
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
CA2435546A1 (en) * 2001-02-08 2002-08-15 Alice C. Martino Rapid-onset medicament for the treatment of sexual dysfunction
ES2180446B1 (es) * 2001-07-02 2004-01-16 Esteve Labor Dr Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
JP4450365B2 (ja) * 2001-08-28 2010-04-14 シェーリング コーポレイション 多環式グアニンホスホジエステラーゼｖ阻害剤
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
JP2005526790A (ja) * 2002-03-19 2005-09-08 ミシェル ホリック アポモルフィンおよび類縁体の配糖体およびオルトエステル配糖体誘導体、ならびにそれらの使用方法
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7037257B1 (en) * 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
TWI330529B (en) * 2003-01-13 2010-09-21 Horphag Res Luxembourg Holding Sa A preparation for improving sperm quality or fertility,a kit comprising the same and uses thereof
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) * 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
CN101027061B (zh) * 2004-05-11 2014-03-12 情感智能有限责任公司 药物制剂及其在治疗女性性功能障碍中的应用
CN106038572A (zh) * 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
RS52671B (sr) 2005-10-12 2013-06-28 Unimed Pharmaceuticals Llc Poboljšani gel testosterona i postupak korišćenja
JP2010518167A (ja) * 2007-02-12 2010-05-27 ディーエムアイ バイオサイエンシズ インコーポレイテッド 併存する早漏及び勃起障害の治療
US20080261991A1 (en) * 2007-02-12 2008-10-23 Dmi Biosciences, Inc. Reducing Side Effects of Tramadol
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US9011864B2 (en) * 2007-12-26 2015-04-21 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
ES2475201T3 (es) * 2007-12-26 2014-07-10 Biotest Ag Agentes dirigidos contra CD138 y usos de los mismos
US9446146B2 (en) * 2007-12-26 2016-09-20 Biotest Ag Methods and agents for improving targeting of CD138 expressing tumor cells
PL2242772T3 (pl) * 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
US20090246298A1 (en) * 2008-03-31 2009-10-01 Ceola P. Steele Viagra
WO2010070617A1 (en) 2008-12-19 2010-06-24 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
CA2761120A1 (en) * 2009-05-06 2010-11-11 Biotest Ag Uses of immunoconjugates targeting cd138
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
WO2012000634A1 (de) 2010-06-29 2012-01-05 Georg Bambach Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
US10117932B2 (en) 2011-12-08 2018-11-06 Biotest Ag Uses of immunoconjugates targeting CD138
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
ATE312609T1 (de) * 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
WO1998052569A1 (en) * 1997-05-19 1998-11-26 Zonagen, Inc. Combination therapy for modulating the human sexual response
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction

Also Published As

Publication number Publication date
PT1173178E (pt) 2005-11-30
ES2244418T3 (es) 2005-12-16
DK1173178T3 (da) 2005-11-07
HUP0200549A2 (hu) 2002-07-29
WO2000054774A1 (en) 2000-09-21
DE60022021D1 (de) 2005-09-22
JP2002539163A (ja) 2002-11-19
BR0009016A (pt) 2002-04-16
PL350313A1 (en) 2002-12-02
MXPA01009332A (es) 2002-06-21
DE60022021T2 (de) 2006-06-08
ATE302003T1 (de) 2005-09-15
EP1173178A1 (en) 2002-01-23
NO324511B1 (no) 2007-11-05
ZA200107920B (en) 2003-03-26
IL145487A0 (en) 2002-06-30
CN1350454A (zh) 2002-05-22
NZ514464A (en) 2004-01-30
NO20014519D0 (no) 2001-09-17
EP1173178B1 (en) 2005-08-17
AU3744500A (en) 2000-10-04
CZ20013344A3 (cs) 2002-08-14
EP1173178A4 (en) 2002-09-04
US6087362A (en) 2000-07-11
CA2367605A1 (en) 2000-09-21
HUP0200549A3 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
NO20014519D0 (no) Apomorfin- og sildenafilpreparat
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
JP2006514092A5 (no)
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
JP2002540148A5 (no)
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
FI20011464A0 (fi) Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
CO5170404A1 (es) Terapia para melanomas
SE0000837D0 (sv) New use
HK1133829A (en) Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
BRPI0503488A (pt) agente de tratamento para sìndrome de intestino irritável com diarréia predominante